Japan's Takeda today officially named French national Christophe Weber its first non-Japanese CEO. The 49-year-old Weber, who takes over April 1, will now have to show whether he can succeed where so many other foreign heads of Japanese companies have not.
Takeda Pharmaceutical officially announced on March 5 that President and Chief Operating Officer Christophe Weber would become chief executive officer staring April 1, replacing Yasuchika Hasegawa.
For more than a year now, NEA general partner David Mott has helmed Mersana Therapeutics, a Cambridge, MA-based biotech that has been working on next-gen antibody-drug conjugates. But this morning he's handing the reins over to longtime biotech vet Anna Protopapas (while remaining chairman) after organizing a $35 million B round that will be announced later this morning.
Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry.
With the hire of Bayer's Olivier Brandicourt as its new CEO, Sanofi will fill the hole it created when it ousted helmsman Chris Viehbacher nearly four months ago. But that means another leadership change is afoot at Brandicourt's current company, which is already in the middle of plenty of shuffling at the top.
Let the proxy fight begin. Activist hedge fund and major Ariad Pharmaceuticals shareholder Sarissa Capital has its own ideas for who it wants in the company's CEO chair--and it's not current helmsman Harvey Berger.
Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...
Sanofi confirmed the rumors today, naming Paris-trained Olivier Brandicourt its new CEO. Brandicourt, who the French drugmaker stole away from the top pharma spot at Bayer HealthCare, will assume the mantle on April 2.
Boehringer Ingelheim's global restructuring--prompted by the German pharma's sales struggle--is now manifesting itself in Connecticut, where the company is laying off staffers in Ridgefield.
A low-profile biotech in Cleveland landed a $30 million B round with the help of a new group of prominent venture backers and has been given a new CEO, a new home in La Jolla and a continuing mission to develop a drug for atrial fibrillation that has quietly moved to the threshold of a Phase III program.